Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The firm is building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/03/21 | $90,000,000 | Series B |
5AM Ventures Access Biotechnology Alexandria Venture Investments Arix Bioscience Atlas Venture Janus Henderson Investors Nantahala Capital Novo Holdings OrbiMed Advisors  Rock Springs Capital Willett Advisors | undisclosed |
